Increasing Prevalence of Cancer across the Globe is Boosting Growth of Chemotherapy Market

Mon, 13 May 2019 6:59

Increasing prevalence of different types of cancers such as lung cancer, sarcoma, lymphoma, breast cancer, myeloma is propelling the growth of the market. According to the World Health Organization (WHO), approximately 17 million people are suffering from cancer across the globe. Chemotherapy kills the primary tumor of the cancer instead of shrinking tumor. Thus, people prefer this treatment to treat the cancer. Moreover, the technological advancement and rising emphasis on research and development in the field of oncology boosting the growth of the market.

Market Segmentation

Geographically, the chemotherapy market is segmented into drugs, indication, route of drug administration, and end-user.

Based on the drugs, the market is segmented into alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and others. Based on the drug, alkylating agents is expected to leading market in the coming year. Alkylating agents are used to treat several cancers.

Based on the indication, the market is segmented into leukemia, lymphoma, breast cancer, ovarian cancer, lung cancer, myeloma, sarcoma, and others.

Based on route of drug administration, the market is segmented into intravenous and oral.

On the basis of end-user, the market is segmented into hospitals, research institutes, and others. Hospital is expected to significant growth in the coming year.

Regional Analysis

Geographically, the market is split into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is likely to holds the largest share in the global chemotherapy market during the forecast period. According to the American Society of Cancer during (2006-2015), approximately 1,762,450 new cancer cases of cancer diagnosed and around 606,880 deaths from cancer are expected to occur in the US in 2019.

Europe is projected to be the second leading region in the global chemotherapy market. Rise in total number of cases of cancer is driving the growth of the chemotherapy market.

Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period 2019–2026. Increasing geriatric and e-smoker population also stimulating the growth of the chemotherapy market.

LAMEA is expecting a steady growth owing to undeveloped healthcare infrastructure. Additionally, lack of awareness about the healthy lifestyle is slowing the cancer treatment market in this region.

Key Players

The global chemotherapy market comprises of various players including Sanofi, Novartis, Pfizer Inc., Eli Lilly & Company, ImClone Systems Inc., GlaxoSmithKline, AstraZeneca, Schering-Plough, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceuticals Industries, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Chemo Espana SL, CELGENE CORPORATION, Amgen Inc, Bayer AG, Takeda Pharmaceutical Company Limited, and others.

Chemotherapy Market Segmentation

By Drug

  • Alkylating Agents
    • Mustard Gas Derivatives
    • Ethylenimines
    • Alkyl Sulfonates
    • Hydrazines
    • Triazines
    • Others
  • Antimetabolites
  • Anti-Tumor Antibiotics
    • Anthracyclines
    • Chromomycin
  • Topoisomerase Inhibitors
    • Topoisomerase I Inhibitors
    • Topoisomerase Ii Inhibitors
  • Mitotic Inhibitors
  • Others

By Indication

  • Leukemia
  • Lymphoma
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Myeloma
  • Sarcoma
  • Others

By Route of Drug Administration

  • Oral
  • Intravenous

By End-User

  • Hospitals
  • Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Key Development

In 2018, Alra Care launched skincare products for chemotherapy patients.

In 2018, Glenmark Pharma launched FDC drug Akynzeo in India for prevention of chemotherapy-induced nausea and vomiting.